Market Research Reports and Industry Reports

Hepatitis C Virus Infection

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
Freedom from injecting Interferon (IFN), treating major HCV genotypes WW and betting on vaccines could bring a sea of change in the treatment of HCV infection in the future. This year the first IFN-free drug options for HCV Genotype 2/3- Gileads Sofosbuvir/RBV (GS-7977, PDUFA Dec. 8, 2013) is expected to be approved and launched! By 2015 launch of Gileads Sofosbuvir/Ledipasvir (PhIII) and AbbVie/ Enantas (ABT-450r/ABT-472/ABT-333) should remove the need of IFN for GT1 genotype HCV patients as well!

Tapping the Bigger Market- ROW: Gilead is moving well towards offering the best treatment options to a broader HCV pt population WW. . Genotype 1 is common in Australia, China, Taiwan and other countries in North Asia, while genotype 6 is found in Vietnam and other Southeast Asian countries. In India and Pakistan, genotype 3 is predominant, while genotype 4 is found in Middle Eastern countries such as Egypt, Saudi Arabia and Syria. A PAN genotype effective drug is what most companies are trying to sequester in their pipeline. This report comprehensively covers the current Standard of Care, its limitations and Future options for the treatment of HCV infection.
Table 1: KEY PRODUCTS IN PIPELINE: IFN-FREE COMBINATION
Table 2 :US & EU MARKET SHARE OF HCV DRUGS IN COMBINATION WITH IFN
Table 3:KEY PIPELINE PRODUCTS VACCINE
Table 4:DATA FROM IFN-FREE COMBINATIONS
Table 5: VIRAL RESPONSE IN GENOTYPE-1 PATIENTS IFN COMBINATIONS
Table 6 :KEY ABSTRACTS OF AASLD 13
KEY MILESTONES TO 2015

List Of Tables

Figure 1 : PTS NOT CANDIDATES FOR IFN-BASED THERAPIES
Figure 2A :SOFOSBUVIR PHIII STUDY DESIGN IN GT2/3 HCV PTS IFN FREE
Figure 2B:SOFOSBUVIR PHIII STUDY DESIGN IN GT 1,4,5,6 HCV PTS IN COMBINATION WITH IFN
Figure 3A:ION-1 SOFOSBUVIR/LEDIPASVIR PHASE 3 FDC STUDY
Figure 3B:ION-2 SOFOSBUVIR/LEDIPASVIR PHASE 3 FDC STUDY
Figure 3C:ION-3 SOFOSBUVIR/LEDIPASVIR PHASE 3 FDC STUDY
Figure: 4A :HCV GENOTYPES IN DIFFERENT PARTS OF THE WORLD
Figure: 4B :HCV PREVALENCE IN DIFFERENT PARTS OF THE WORLD
Figure 5: ABBVIEs IFN-FREE COMBINATIONS PHIII DESIGNS
Figure 6 :SIMEPREVIR IFN-FREE COMBINATIONS
Chart 1A :US & EU MARKET SHARE OF HCV DRUGS IN COMBINATION WITH IFN
Chart 1B :US & EU MARKET SHARE OF IFN-FREE COMBINATION HCV DRUGS
Figure 7 :HIV & HCV CO-INFECTION
Figure 8 :DIFFERENCE BETWEEN HIV & HCV

List Of Figures

Table 1: KEY PRODUCTS IN PIPELINE: IFN-FREE COMBINATION
Table 2 :US & EU MARKET SHARE OF HCV DRUGS IN COMBINATION WITH IFN
Table 3:KEY PIPELINE PRODUCTS VACCINE
Table 4:DATA FROM IFN-FREE COMBINATIONS
Table 5: VIRAL RESPONSE IN GENOTYPE-1 PATIENTS IFN COMBINATIONS
Table 6 :KEY ABSTRACTS OF AASLD 13
KEY MILESTONES TO 2015

United States Hepatitis Drugs Market Report 2017

Notes:Sales, means the sales volume of Hepatitis DrugsRevenue, means the sales value of Hepatitis DrugsThis report studies sales (consumption) of Hepatitis Drugs in United States market, focuses on the top

USD 3800View Report

Global Hepatitis Drugs Market Professional Survey Report 2017

Notes:Production, means the output of Hepatitis DrugsRevenue, means the sales value of Hepatitis DrugsThis report studies Hepatitis Drugs in Global market, especially in North America, China, Europe, Southeast Asia, Japan

USD 3500View Report

Global Hepatitis Drugs Market Research Report 2017

Notes:Production, means the output of Hepatitis DrugsRevenue, means the sales value of Hepatitis DrugsThis report studies Hepatitis Drugs in Global market, especially in North America, Europe, China, Japan, Southeast Asia

USD 2900View Report

EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2025

EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2025Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV). HCV can cause both acute and chronic

USD 3995View Report

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Hepatitis C is a blood-borne viral infection characterized by chronic inflammation of the

USD 6995View Report

Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2016

Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2016Global Markets Directs, Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2016, provides in depth analysis on Hepatitis

USD 3500View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 1000
  • Site Licence    $ 2000
  • Enterprisewide Licence    $ 3000
$ 1000

Reports Details

Published Date : Oct 2013
No. of Pages :33
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment